Preoperative treatment of anemia—could an ultra-short-term multimodal approach be beneficial for patients undergoing lung surgery?

Sebastian Heinrich, Torsten Loop


Lung cancer is the most common malignant neoplasm and the leading cause of cancer related death worldwide (1). Advances in treatment of patients with lung cancer have not significantly improved overall survival throughout the last decades (2,3). To increase the patients’ benefit from lung surgery and to reduce intervention related morbidity and mortality, perioperative programs mainly addressing pulmonary complications have been established (4-6). As part of preoperative optimization the treatment of anemia moved more and more into the focus within in the last years.